The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions

Gklinos, Panagiotis; Mitsikostas, Dimos D.

doi:10.3390/ph14030245

Cited by 4 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of our patients and physicians considered galcanezumab to be effective or very effective at each visit, and the reported TEAEs in our cohort were consistent with the well-known high safety and tolerability profile of galcanezumab (16,18). In this context, our findings support the notion that the high tolerability of galcanezumab, facilitated by its monthly administration and sustained effectiveness, establishes a significant foundation for improved adherence and, ultimately, enhanced outcomes in patients with both EM and CM (52,59).…”

Section: Discussionsupporting

confidence: 85%

“…HIT-6 scores exhibited a baseline value of 67 (65-70) and significantly decreased to 58 (50-62), 57 (48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62), and 56 (49-63) at the 1st, 2nd, and 3rd month visits, respectively (p < 0.001 for each). Additionally, MIDAS scores demonstrated marked improvement from baseline to the 3rd month, decreasing from 50 (0-180) to 9 (0-70) (p < 0.001) (Table 4).…”

Section: Headache Impact and Migraine-related Disabilitymentioning

confidence: 93%

See 1 more Smart Citation

Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine

Ilgaz Aydinlar,

Erdogan Soyukibar,

Yalinay Dikmen

2024

Front. Neurol.

View full text Add to dashboard Cite

IntroductionThis real-world study aimed to investigate the impact of galcanezumab on sleep quality, migraine outcome and multidimensional patient-reported outcomes measures (PROMs) in patients with episodic migraine (EM) and chronic migraine (CM).MethodsFifty-four patients with episodic migraine (n = 24) or chronic migraine (n = 30) received a 3-month series of galcanezumab injections and were evaluated for sleep quality, measured using the Pittsburgh Sleep Quality Index (PSQI), as well as migraine outcomes such as monthly headache days (MHDs), monthly migraine days (MMDs), and headache severity. Patient-reported outcome measures (PROMs) such as the Migraine Disability Assessment Scale (MIDAS), Headache Impact Test-6 (HIT-6), SF-36 Health-related Quality of Life (HRQoL), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI) were additionally included in the assessment.ResultsThe percentage of patients with poor sleep quality (total PSQI scores ≥ 5) was 72.7% at baseline, decreasing to 57.5% and 56.2% at the 1st and 2nd months, respectively. By the 3rd month of galcanezumab injections, significant improvement was observed in the sleep disturbances domain in the overall study population (p = 0.016), and in subgroups of patients with low anxiety levels (p = 0.016) and none/minimal depression (p = 0.035) at baseline. Patients with sleep disorder at baseline exhibited marked improvements in total PSQI scores (p = 0.027) and in the subjective sleep quality (p = 0.034) and daytime dysfunction (p = 0.013) domains, by the 3rd month. Over the 1st, 2nd, and 3rd months, there were significant improvements in MHDs (p < 0.001), MMDs (p < 0.001), HIT-6 scores (p < 0.001 for each), BAI scores (p < 0.001 for each), BDI scores (p ranged from 0.048 to <0.001), and HRQoL scores (p ranged from 0.012 to <0.001).ConclusionGalcanezumab demonstrates notable benefits in improving sleep quality, along with a comorbidity-based and domain-specific effect on sleep parameters, which involved sleep disturbances domain in patients without depression or anxiety at baseline but the total PSQI scores, subjective sleep quality and daytime dysfunction in those with sleep disorder at baseline. The treatment also facilitates rapid-onset enhancements in migraine outcomes as well as various PROMs.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Headache Impact and Migraine-related Disabilitymentioning

confidence: 93%

Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine

Ilgaz Aydinlar,

Erdogan Soyukibar,

Yalinay Dikmen

2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Eptinezumab, fremanezumab, and galcanezumab selectively bind to the CGRP itself as a ligand, while erenumab competitively and reversibly targets CGRP receptor components. All of the above-mentioned mAbs are highly effective and safe in the prophylaxis of both EM and CM [ 5 , 17 , 60 , 61 , 62 , 63 ].…”

Section: Calcitonin Gene-related Peptide Function In Migraine and Neu...mentioning

confidence: 99%

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain

Tajti

Delia

Csáti

et al. 2023

IJMS

View full text Add to dashboard Cite

Migraine and neuropathic pain (NP) are both painful, disabling, chronic conditions which exhibit some symptom similarities and are thus considered to share a common etiology. The calcitonin gene-related peptide (CGRP) has gained credit as a target for migraine management; nevertheless, the efficacy and the applicability of CGRP modifiers warrant the search for more effective therapeutic targets for pain management. This scoping review focuses on human studies of common pathogenic factors in migraine and NP, with reference to available preclinical evidence to explore potential novel therapeutic targets. CGRP inhibitors and monoclonal antibodies alleviate inflammation in the meninges; targeting transient receptor potential (TRP) ion channels may help prevent the release of nociceptive substances, and modifying the endocannabinoid system may open a path toward discovery of novel analgesics. There may exist a potential target in the tryptophan-kynurenine (KYN) metabolic system, which is closely linked to glutamate-induced hyperexcitability; alleviating neuroinflammation may complement a pain-relieving armamentarium, and modifying microglial excitation, which is observed in both conditions, may be a possible approach. Those are several potential analgesic targets which deserve to be explored in search of novel analgesics; however, much evidence remains missing. This review highlights the need for more studies on CGRP modifiers for subtypes, the discovery of TRP and endocannabinoid modulators, knowledge of the status of KYN metabolites, the consensus on cytokines and sampling, and biomarkers for microglial function, in search of innovative pain management methods for migraine and NP.

show abstract

“…Eptinezumab, fremanezumab and galcanezumab selectively bind to CGRP itself as a ligand, while erenumab competitively and reversibly targets CGRP receptor components. All of the above mentioned mAbs are highly effective and safe in the prophylaxis of both EM and CM [5,17,[38][39][40][41].…”

Section: Migrainementioning

confidence: 99%

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain

Tajti¹,

Delia²,

Csáti³

et al. 2023

Preprint

View full text Add to dashboard Cite

Migraine and neuropathic pain (NP) are evocative of painful, disabling, chronic conditions which exhibit resembling symptoms and thus considered to share a common etiology. Calcitonin gene-related peptide (CGRP) has gained credit as a target for migraine management; nevertheless, the efficacy and the applicability of CGRP modifiers warrant search for more effective therapeutic targets for pain management. This scoping review overviews human studies of common pathogenic factors in migraine and NP to explore potential novel therapeutic targets. CGRP causes inflammation in the meninges; monoclonal antibodies and inhibitors target CGRP. Gluta-mate-induced hyperexcitability and subsequent sensitization are closely linked to an alteration of the tryptophan (Trp)-kynurenine (KYN) metabolic system; the Trp-KYN system may serve as a potential target. Microglial overaction is observed in migraine and NP; modifying the microglial activity may be a possible approach. Cytokine-induced inflammation is a leading hypothesis of the pathogenesis of the conditions; alleviating neuroinflammation may complement a pain-relieving armamentarium. Transient receptor potential (TRP) ion channels evoke the release of several substances; TRP ion channels may potentially emerge as new targets. The endocannabinoid system plays a major role in the pain trafficking pathway; modification of the system may open a new path toward discovery of new analgesics. Here we highlight the mechanism of those common pathogenic factors to explore therapeutic targets for innovative pain management in migraine and NP.

show abstract

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions

Cited by 4 publications

References 40 publications

Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine

Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain

Contact Info

Product

Resources

About